Clinical Trials Browser

lonafarnib × Clear all

NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Phase 1 Active not recruiting

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

NCT00102635 2018-11-15

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Terminated

Head and Neck Neoplasms

NCT00005030 2018-11-14

SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver

Phase 1 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00047502 2018-11-07

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00038584 2018-10-30

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

Phase 1 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Phase 2 Completed

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00773474 2016-02-18

Lonafarnib in Metastatic Breast Cancer

Phase 2 Terminated

29 enrolled 11 charts

Breast Neoplasms

NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Phase 3 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00081510 2015-04-15

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Phase 2 Completed

Breast Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Phase 1/2 Terminated

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Phase 1 Terminated

BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00006351 2012-09-24

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00281515 2012-06-29

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial

NCT00015899 2009-10-14

SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Phase 1 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma